---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-000937"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:03:48.983821+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Autonomix reports pancreatic cancer pain relief across all stages in PoC study at ASCO GI 2026

## Summary
- Rapid pain reduction within 24 hours of transvascular RF denervation procedure.
- At 7 days, 93.75% of responding patients (N=16) improved from severe to mild/moderate pain.
- At 4-6 weeks, ~2/3 of responders (N=9) maintained mild or eliminated pain levels.
- At 3 months, no responders (N=6) had severe pain; 50% maintained mild or eliminated pain.
- Even late-stage (Stage 4) patients showed meaningful early improvement despite disease progression.

## SEC filing metadata
- accession: 0001437749-26-000937
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774926000937/0001437749-26-000937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774926000937/amix20260108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-000937
- JSON: https://secwatch.observer/filing/0001437749-26-000937.json
- Plain text: https://secwatch.observer/filing/0001437749-26-000937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.